PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy
TARRYTOWN, New York, May 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- PaxMedica, Inc. (OTC:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, provided a corporate update in light of its transition off the NASDAQ stock market, emphasizing this change will not affect the company's commitment to advancing treatments for neurological disorders.
紐約塔裏敦，2024年5月7日（GLOBE NEWSWIRE）——通過IBN——專注於推進神經系統疾病治療的生物製藥公司PaxMedica, Inc.（場外交易代碼：PXMD）根據其從納斯達克股票市場過渡的情況提供了公司最新情況，強調這一變化不會影響該公司推進神經系統疾病治療的承諾。
Howard Weisman, CEO of PaxMedica, affirmed, "Our determination to progress with the NDA submission for PAX-101 remains unaffected, as does our commitment to our clinical program to further explore the potential for anti-purinergic therapies to address the core symptoms of autism spectrum disorder (ASD)."
PaxMedica 首席執行官霍華德·韋斯曼申明：“我們在 PAX-101 保密協議提交方面取得進展的決心沒有受到影響，我們對進一步探索抗嘌呤能療法解決自閉症譜系障礙 (ASD) 核心症狀潛力的臨床項目承諾也沒有受到影響。”
The company is preparing to file a New Drug Application (NDA) with the FDA for the use of suramin in treating Human African Trypanosomiasis (HAT) as it has previously reported. Suramin has been recognized for nearly a century as a standard treatment for HAT in East Africa.
正如其先前報道的那樣，該公司正準備向美國食品藥品管理局提交新藥申請（NDA），以使用舒拉明治療非洲人類錐蟲病（HAT）。近一個世紀以來，舒拉明一直被公認爲東非HAT的標準治療方法。
In April 2024, PaxMedica responded to an urgent request from Malawi for an emergency release of suramin, underscoring the company's commitment to addressing global health crises.
2024年4月，PaxMedica回應了馬拉維提出的緊急釋放舒拉明的緊急請求，這突顯了該公司對解決全球健康危機的承諾。
"We are not just continuing; we are intensifying our efforts to achieve significant milestones for these programs by the end of this year," Weisman added. "We are on track to submit an NDA for PAX-101, and potentially secure an FDA Priority Review Voucher if approved."
韋斯曼補充說：“我們不僅在繼續；我們還在加緊努力，爭取在今年年底之前實現這些計劃的重大里程碑。”“我們有望提交 PAX-101 的保密協議，如果獲得批准，我們有可能獲得美國食品藥品管理局的優先審查憑證。”
This proactive approach illustrates PaxMedica's dedication to advancing healthcare solutions globally.
這種積極的方法表明了PaxMedica致力於在全球範圍內推進醫療保健解決方案的決心。